Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.385 EUR | +1.90% | +1.73% | -5.43% |
29/04 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
14/03 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Evolution of the average Target Price on Clinuvel Pharmaceuticals Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Clinuvel Pharmaceuticals Limited
Morgans Financial |
EPS Revisions
- Stock Market
- Equities
- CUV Stock
- UR9 Stock
- Consensus Clinuvel Pharmaceuticals Limited